About Oncoceutics
Oncoceutics is a company based in Philadelphia (United States) founded in 2009 was acquired by Chimerix in January 2021. The company has 18 employees as of December 31, 2020. Oncoceutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Philadelphia, United States
- Employees 18 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Oncoceutics
Investors in Oncoceutics
Oncoceutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Chimerix and Spring Mountain Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Antiviral oral therapeutics are developed for infectious diseases and cancers.
|
Locked | Locked | Locked |
Investor details for Oncoceutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Oncoceutics
Investment portfolio details for Oncoceutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oncoceutics
Detailed financials for Oncoceutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncoceutics Comparisons
Peer comparison for Oncoceutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oncoceutics
Oncoceutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Oncoceutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncoceutics
Complete news archive for Oncoceutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncoceutics
Oncoceutics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Oncoceutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
As of Dec 31, 2020, the latest employee count at Oncoceutics is 18.
Oncoceutics is a clinical-stage drug development company focused on oncology. Oncoceutics is developing ONC201, an oral, small-molecule drug that acts against numerous tumor types by sparing healthy cells and targeting the most potent tumor suppressor pathways. The company is currently in clinical trials at cancer centers including Massachusetts General Hospital, Rutgers Cancer Institute of New Jersey, Fox Chase Cancer Center, and at the University of Texas MD Anderson Cancer Center. ONC201 is in multiple trials at various stages and several analogs with differentiated profiles in preclinical testing. ONC201 is an Imipridone- Imipridones are a novel class of small molecule anti-cancer compounds that possess a unique three-ring heterocyclic core structure with two substitutable basic amines. ONC201, which directly antagonizes a GPCR called DRD2.
Oncoceutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Oncoceutics has 3 investors. Key investors include HHS, Chimerix, and Spring Mountain Capital.